Related Experiment Video
Updated: Mar 28, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC
Ondrej Fiala1, Milos Pesek2, Jindrich Finek3
1Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Prague, Czech Republic Biomedical Center, Faculty of Medicine in Pilsen, Faculty of Sciences, Charles University in Prague, Prague, Czech Republic fiala.o@centrum.cz.
Background:
Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) represent novel, effective tools in the management of advanced-stage non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence and predictive role of EGFR gene amplification in patients with advanced-stage NSCLC treated with EGFR-TKIs.
Patients And Methods:
The study included 290 patients with advanced-stage (IIIB or IV) NSCLC. Multiplex ligation-dependent probe amplification (MLPA) and polymerase chain reaction (PCR) were used for detection of EGFR gene amplification and EGFR mutations, respectively.
Results:
EGFR amplification was detected in 26 (9.0%) patients. EGFR amplification was found more frequently in patients harboring the EGFR mutation (p<0.001). No significant corelation between EGFR gene amplification and survival was observed.
Conclusion:
EGFR gene amplification is associated with EGFR gene mutation. EGFR gene amplification is not a feasible predictive biomarker for treatment with EGFR-TKIs in patients with advanced-stage NSCLC.
Insights
Epidermal growth factor receptor (EGFR) gene amplification occurs in 9% of advanced non-small cell lung cancer (NSCLC) patients. Amplification is linked to EGFR mutations but does not predict treatment response to EGFR-TKIs.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for advanced non-small cell lung cancer (NSCLC).
- The role of EGFR gene amplification as a predictive biomarker for EGFR-TKI treatment in NSCLC requires further investigation.
Purpose of the Study:
- To determine the incidence of EGFR gene amplification in advanced NSCLC patients treated with EGFR-TKIs.
- To assess the association between EGFR gene amplification and EGFR mutations.
- To evaluate the predictive value of EGFR gene amplification for treatment response.
Main Methods:
- Included 290 patients with advanced-stage (IIIB or IV) NSCLC.
- Utilized multiplex ligation-dependent probe amplification (MLPA) for EGFR gene amplification detection.
- Employed polymerase chain reaction (PCR) for EGFR mutation analysis.
Main Results:
- EGFR gene amplification was detected in 9.0% (26/290) of patients.
- EGFR amplification was significantly more frequent in patients with EGFR mutations (p<0.001).
- No significant correlation was observed between EGFR gene amplification and patient survival.
Conclusions:
- EGFR gene amplification is associated with EGFR gene mutations in NSCLC.
- EGFR gene amplification is not a reliable predictive biomarker for EGFR-TKI therapy in advanced NSCLC.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:38Mitogens and the Cell Cycle
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...